Unknown

Dataset Information

0

TERT Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients.


ABSTRACT: Telomerase reverse transcriptase gene promoter (TERTp) mutations are recognized as one of the most frequent genetic events in bladder cancer (BC). No studies have focused on the relevance of TERTp mutations in the specific group of tumors treated with Bacillus Calmette-Guérin (BCG) intravesical therapy. Methods - 125 non muscle invasive BC treated with BCG therapy (BCG-NMIBC) were screened for TERTp mutations, TERT rs2853669 single nucleotide polymorphism, and Fibroblast Growth Factor Receptor 3 (FGFR3) hotspot mutations. Results - TERTp mutations were found in 56.0% of BCG-NMIBC and were not associated with tumor stage or grade. FGFR3 mutations were found in 44.9% of the cases and were not associated with tumor stage or grade nor with TERTp mutations. The TERT rs2853669 single nucleotide polymorphism was associated with tumors of higher grade. The specific c.1-146G>A TERTp mutation was an independent predictor of nonrecurrence after BCG therapy (hazard ratio-0.382; 95% confidence interval-0.150-0.971, p = 0.048). Conclusions - TERTp mutations are frequent in BCG-NMIBC and -146G>A appears to be an independent predictive marker of response to BCG treatment with an impact in recurrence-free survival.

SUBMITTER: Batista R 

PROVIDER: S-EPMC7037401 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

<i>TERT</i> Promoter Mutation as a Potential Predictive Biomarker in BCG-Treated Bladder Cancer Patients.

Batista Rui R   Lima Luís L   Vinagre João J   Pinto Vasco V   Lyra Joana J   Máximo Valdemar V   Santos Lúcio L   Soares Paula P  

International journal of molecular sciences 20200131 3


Telomerase reverse transcriptase gene promoter (<i>TERTp</i>) mutations are recognized as one of the most frequent genetic events in bladder cancer (BC). No studies have focused on the relevance of TERTp mutations in the specific group of tumors treated with Bacillus Calmette-Guérin (BCG) intravesical therapy. Methods - 125 non muscle invasive BC treated with BCG therapy (BCG-NMIBC) were screened for <i>TERTp</i> mutations, <i>TERT</i> rs2853669 single nucleotide polymorphism, and Fibroblast Gro  ...[more]

Similar Datasets

| S-EPMC7915609 | biostudies-literature
| S-EPMC4637304 | biostudies-literature
| S-EPMC5245983 | biostudies-literature
| S-EPMC7281483 | biostudies-literature
| S-EPMC4631186 | biostudies-literature
| S-EPMC5464302 | biostudies-literature
| S-EPMC7463448 | biostudies-literature
| S-EPMC4462090 | biostudies-literature
| S-EPMC4350803 | biostudies-literature